Table 2 Clinicopathologic correlation of HLA-I expression type accordign to the tumour location.
Centre of tumour | Invasive margin | |||||||
|---|---|---|---|---|---|---|---|---|
HLA-I preserved | HLA-I total loss | Total | P value | HLA-I preserved | HLA-I total loss | Total | P value | |
Age | ||||||||
<65 | 51 (53.1%) | 45 (46.9%) | 96 | 0.377 | 60 (62.5%) | 36 (37.5%) | 96 | 1.000 |
≥65 | 110 (55.8%) | 87 (44.2%) | 197 | 123 (62.4%) | 74 (37.6%) | 197 | ||
Sex | ||||||||
Male | 99 (55.0%) | 81 (45.0%) | 180 | 0.539 | 114 (63.3%) | 66 (36.7%) | 180 | 0.711 |
Female | 62 (54.9%) | 51 (45.1%) | 113 | 69 (61.1%) | 44 (38.9%) | 113 | ||
pT stage | ||||||||
pT1 | 80 (56.7%) | 61 (43.3%) | 141 | 0.317 | 95 (67.4%) | 46 (32.6%) | 141 | 0.116 |
pT2–4 | 81 (53.3%) | 71 (46.7%) | 152 | 88 (57.9%) | 64 (42.1%) | 152 | ||
pN stage | ||||||||
pN0 | 99 (55.6%) | 79 (44.4%) | 178 | 0.434 | 115 (64.6%) | 63 (35.4%) | 178 | 0.388 |
pN1–3 | 62 (53.9%) | 53 (46.1%) | 115 | 68 (59.1%) | 47 (40.9%) | 115 | ||
Distant metastasis | ||||||||
Absent | 158 (44.8%) | 128 (55.3%) | 286 | 0.392 | 178 (62.2%) | 108 (37.8%) | 286 | 0.715 |
Present | 4 (57.1%) | 3 (42.9%) | 7 | 5 (71.4%) | 2 | 7 | ||
CD3+ TIL density | ||||||||
Low | 67 (45.6%) | 80 (54.4%) | 147 | 0.001 | 71 (48.3%) | 76 (51.7%) | 147 | <0.001 |
High | 94 (64.4%) | 52 (35.6%) | 146 | 112 (76.7%) | 34 (23.3%) | 146 | ||
CD8+ TIL density | ||||||||
Low | 71 (48.6%) | 75 (51.4%) | 146 | 0.002 | 80 (54.4%) | 67 (45.6%) | 147 | 0.005 |
High | 90 (61.2%) | 57 (38.8%) | 147 | 103 (70.5%) | 43 (29.5%) | 146 | ||
PD-L1 CPS | ||||||||
Negative | 65 (50.4%) | 64 (49.6%) | 129 | 0.101 | 77 (57.9%) | 56 (42.1%) | 133 | 0.089 |
Positive | 96 (58.5%) | 68 (41.5%) | 164 | 106 (66.3%) | 54 (33.8%) | 160 | ||
PD-L1 TPS | ||||||||
Negative | 103 (52.3%) | 94 (47.7%) | 197 | 0.117 | 118 (57.0%) | 89 (43.0%) | 207 | 0.002 |
Positive | 58 (60.4%) | 38 (39.6%) | 96 | 65 (75.6%) | 21 (24.4%) | 86 | ||
Total | 161 | 132 | 293 | 183 | 110 | 293 | ||
